Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma

The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, cisplatin) in transplant-eligible patients with mantle cell lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa, Diego, Hoster, Eva, Hermine, Olivier, Klapper, Wolfram, Szymczyk, Michal, Bosly, André, Unterhalt, Michael, Rimsza, Lisa M., Ramsower, Colleen A., Freeman, Ciara L., Scott, David W., Gerrie, Alina S., Savage, Kerry J., Sehn, Laurie H., Dreyling, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631687/
https://www.ncbi.nlm.nih.gov/pubmed/35439293
http://dx.doi.org/10.1182/bloodadvances.2022007371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631687/
https://www.ncbi.nlm.nih.gov/pubmed/35439293
http://dx.doi.org/10.1182/bloodadvances.2022007371

Ejemplares similares